Giorgio Palma

Giorgio De Palma is a Senior Managing Director (Partner) at CVC Capital Partners, one of the world's largest private equity and investment firms, where he is a senior member of the CVC Italy team based in Milan. He joined CVC in 2005 and has spent roughly two decades building the firm's Italian franchise, leading control-oriented buyouts of established Italian businesses. Prior to CVC, he spent over four years in the Mergers & Acquisitions team at Morgan Stanley.

De Palma has a strongly technical academic background for a private equity investor. He holds an MSc in Nuclear Engineering from the Politecnico di Milano and an MSc in Industrial Engineering from the École Centrale de Paris — a profile well suited to CVC's heavy emphasis on Italian industrial and manufacturing assets.

Over his career he has held numerous board seats on CVC portfolio companies, reflecting his hands-on role in governance and value creation. These have included Recordati S.p.A. (pharmaceuticals), Sisal S.p.A. (gaming/betting), Multiversity S.p.A. (online higher education), Conceria Pasubio S.p.A. (automotive leather), Cerved Information Solutions S.p.A. (credit and information services), and Lecta S.A. (specialty paper). He was also closely involved in CVC's ownership of DOC Generici, the Italian generic-pharmaceuticals leader.

It is worth flagging that the intake stub described him as an "Angel Investor" doing "Seed Rounds." Research does not support this: he is a large-cap private equity partner doing control buyouts. The email domain (cvc.com) and phone contact are consistent with CVC's Milan operations.

• Invests through CVC's flagship buyout funds in control/majority stakes of mature, market-leading companies — not early-stage or seed venture deals.
• Focus on Italian and Southern European champions, frequently family- or founder-owned businesses where CVC provides capital and expertise for international growth and generational transition (e.g., the Reggiani family with Clevertech).
• Prefers high-quality, cash-generative businesses with strong organic growth — his own framing of DOC Generici was that it was "a high-quality business with strong organic growth and high cash generation."
• Sector emphasis on industrials/industrial automation, healthcare & pharma, consumer, gaming, and business/information services.
• On the Clevertech deal he stated CVC was "proud to invest in Clevertech Group, a global leader in industrial automation, and… excited to support the Reggiani family in its investment plans and international development" — signaling a thesis of backing global-leader industrials and partnering with founding families on cross-border expansion.